selpercatinib (TBC)


( Last Updated : July 16, 2021)
Generic Name:
selpercatinib
Project Status:
Pending
Therapeutic Area:
RET fusion-positive non-small cell lung cancer
Manufacturer:
Eli Lilly Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
PC0261-000
Call for patient/clinician input closed:
Tumour Type:
Lung

Details


Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Indicated as monotherapy for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients.
Anticipated Date: